Sufficiently graft-ifying

Opsona Therapeutics Ltd. took the rare step of turning down money in last week's series C round, as the immunology company capped the financing at €33 million ($43 million) to avoid dilution. The high number of corporate venture funds that participated in the round suggests Opsona will not have trouble attracting a partner - and thus